ARCHIVES

FDA cancer therapeutics review split among three units in reorganization.

This article is from The Cancer Letter archive.

Vol. 29 No. 37 | October 10, 2003

Download PDF Visit The Full Archive

Related Articles

Organ Systems Support Contract To Cost More than OSCC Grant

September 30, 1988

Regorafenib Trial Meets Primary Endpoint; Overall Survival Improved by 29 Percent

January 27, 2012

The Philadelphia Story: How Surprise Filing by Abramson Spurred Penn to Follow Suit

March 16, 2012

NCI to release RFP for Cancer Information Service recompetition.

November 28, 2003

NCI Advisors Approve Center Grants For Research On Health Disparities.

November 30, 2001

Mandates Not welcome In Steady State Funding, Varmus Tells Senate

March 15, 1996